EPIDEMIC PROCESS AND VACCINE PROPHYLAXIS OF PERTUSSIS


Cite item

Full Text

Abstract

Analysis of data on epidemic process of pertussis infection in conditions of wide coverage of population by prophylactic vaccination is presented. Post-vaccination immunity against pertussis was shown to reduce with age; therefore a large part of vaccinated children becomes susceptible to this infection already in primary school age. Epidemic process of pertussis continues both as manifest form and as subclinical and atypical forms. The main reservoir of pertussis infection is older age population groups. The necessity to implement programs of revaccination against pertussis in older children, adolescents and adults is justified. Characteristics of vaccines for immune prophylaxis of pertussis infection are given.

About the authors

E. M Zaytsev

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

References

  1. Бабаченко И.В. Современные представления об иммуногенности и профилактической эффективности бесклеточных АКДС - вакцин на основе антигенов коклюшной палочки. Вопросы современной педиатрии. 2005, 4 (5): 35-41.
  2. Бабаченко И.В., Курова Н.Н., Ценева Г.Я. Коклюшная инфекция в условиях антигенного дрейфа Bordetella pertussis. Вопросы современной педиатрии. 2006, 5 (6): 25-27.
  3. Зайцев Е.М., Мазурова И.К., Краснопрошина Л.И. и др. Гуморальный противококлюшный иммунитет и распространенность коклюша в популяции. Журн. микробиол. 2009, 1: 56-58.
  4. Зайцев Е.М., Мазурова И.К., Петрова М.С. и др. Совершенствование диагностики коклюша у взрослых с длительным кашлем. Журн.микробиол. 2009, 2: 70-75.
  5. Зайцев Е.М., Краснопрошина Л.И., Астахова Т.И., Захарова Н.С. Мониторинг противодифтерийных, противостолбнячных и противококлюшных антител у беременных женщин. Журн.микро-биол. 2010, 1: 32-35.
  6. Захарова М.С. Эпидемиология коклюша и некоторые предпосылки экономического эффекта вакцинации. Журн.микробиол. 1974, 4: 3-9.
  7. Наркевич М.И., Тымчаковская И.М. Инфекционная заболеваемость в России. Журн.микробиол. 1997, 3: 48-52.
  8. Таточенко В.К. Перспективы развития иммунопрофилактики в России. Журн. микробиол. 2010, 5: 90-98.
  9. Таточенко В.К., Озерецковский Н.А., Федоров А.М. Иммунопрофилактика (справочник). М., Континент-Пресс, 2011.
  10. Bass J.W., Stephenson S.R. The return of pertussis. Pediatr. Infect. Dis. J. 1987, 6: 141-144.
  11. American Academy ofPediatrics. Pertussis (Whooping Cough). In: Pickering L.K., Baker C.J., Kimberlin D.W, Long S.S. (ed). Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Groove Village, IL, American Academy of Pediatrics, 2009.
  12. Bouziri A., Hamdi A., Khaldi A. et al. Malignant pertussis an underdiagnosed illness. Med. Trop. (Mars). 2010, 70 (3): 245-248.
  13. Brooks D.A., Clover R. Pertussis infection in the United States role for vaccination of adolescents and adults. J. Am. Board Fam. Med. 2006, 19 (6): 603-611.
  14. Calugar A., Ortega-Sanchez I.R., Tiwari T. et al. Nosocomial pertussis cost of an outbreak and benefits of vaccinating health care workers. Clin. Infect. Dis. 2006, 42 (7): 981-988.
  15. Campbell P., McIntyre P., Quinn H. et al. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS ONE, 2012, 7 (4): e35874.
  16. Cherry J.D. The epidemiology ofpertussis: a comparison ofthe epidemiology ofthe disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics. 2005, 115 (5): 1422-1427.
  17. Crameri S., Heininger U. Successful control of a pertussis outbreak in a university children hospital. Int. J. Infect. Dis. 2008, 12 (6): 85-87.
  18. De Greeff S.C., Mooi F.R., WesterhofA. et al. Pertussis disease burden in the household: how to protect young infants. Clin. Infect. Dis. 2010, 50 (10):1339-1345.
  19. De Melker H.E., Versteegh F.G., Schelltkens J.F. et al. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J.Infect. 2006, 532: 106113.
  20. European Centre for Disease Prevention and Control. Pertussis vaccination overview in European coun-tries//URL: httр//ecdc.europa.eu/en/activities/surveillance/euvac/schedules/Pages/pertussis_schedule. aspx (по состоянию на 30.05.2012).
  21. Hallander H.O., Nilsson L., Gustafsson L. Is adolescent pertussis vaccination preferable to natural booster infections? Expert. Rev. Clin. Pharmacol. 2011, 4 (6): 705-711.
  22. Halperin S.A., McNeil S., Langley J. et al. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine. 2011, 29 (46): 8459-8465.
  23. He Q., Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 2008, 3 (3): 329339.
  24. Hewlett E., Edvards K.M. Pertussis - not Just for kids. N. Engl. J. Med. 2005, 352: 1215-1222.
  25. Higa F., Haranaga S., Tateyama M. et al. Assesment of serum anti - Bordetella pertussis antibody titers among medical staff members. Jpn. J. Infect. Dis. 2008, 61 (5): 371-374.
  26. Gonic B., Puder K.S., Gonic N., Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. M. Infect. Dis. Obstet. Gynecol. 2005, 13 (2): 59-61.
  27. Leung A.K., Robson W.L., Davies H.D. Pertussis in adolescents. Ther. 2007, 24 (2): 353-361.
  28. Miller E., Fleming D.M., Ashworth L.A. et al. Seroligical evidence of pertussis in patients presenting with cough in general practice in Birmingam. Comm. Dis. Public. Health. 2000, 3 (2): 132-134.
  29. Public Health Agency of Canada. Immunization schedules: Reccomendations from the National Advisory Committee on Immunization. URL: http://www.phac-aspc.gc.ca/im/is-cv/index-eng.php (по состоянию на 30.05.2012).
  30. Riffelman M., Littman M., Hulfle C. et al. Pertussis: Not only a disease of childhood. Dtsch. Arztebl. Int. 2008, 105 (37): 623-628.
  31. Riffelman M., Wirsing von Konig C.H. Lifelong protection against pertussis. Dtsch. Med. Wochenschr. 2009, 134 (2): S86-S89.
  32. Schellekens J., von Konig C.H., Gardner P. Pertussis sources and routes of transmissijn in the vaccination era. Pediatr. Infect. Dis. J. 2005, 24 (5): S19-S24.
  33. Skoff T.H., Cohn A.C., Clark T.A. et al. Early impact of the US Tdap vaccination program on pertussis trends.Arch. Pediatr. Adolesc. Med. 2012, 166 (4): 344-349.
  34. Scott L.J. Tdap vaccine (Covaxis): a review of its use as a single - booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescens, and adults. BioDrugs. 2010, 24 (6): 387-406.
  35. Skerry C.M., Mahon B.P. A live attenuated Bordetella pertussis vaccine provides long term protection against virulent challenge in a murine model. Clin. Vaccine Immunol. 2011, 18 (2): 187-193.
  36. Strebel P., Nordin J.,Edwards K. et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J. Infect. Dis. 2001, 183 (9):1353-1359.
  37. Tan T, Trindade E., Scowronski D. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 2005, 24 (5):10- 18.
  38. Tomovici A., Barreto L, Zickler P. et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine. 2012, 30 (16): 2647-2653
  39. US Department ofHealth and Human Services. Centers for Disease Control and Prevention. Immunization Schedules, 2012. URL: http://www.cdc.gov/vaccines/recs/schedules/ (по состоянию на 30.05.2012).
  40. Versteegh F.G., Schellekens J.F., Nagelkerke A.F., Roord J.J. Laboratory - confirmed reinfection with Bordetella pertussis. Acta Paediatr. 2002, 91 (1): 95-97.
  41. Ward J.I., Cherry J.D., Chang S.J. et al. Bordetella pertussis infection in vaccinated and unvaccinated adolescents and adults in a national prospective randomized Acellural Pertussis Vaccine Trial (APERT). Clin.Infect. Dis. 2006, 43 (2): 151-157.
  42. Wearing H.J., Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLos Pathog. 2009, 5 (10): e1000647.
  43. Wei Stanley C., Tatti K., Cushing K. et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin. Infect. Dis. 2010, 51 (3): 315321.
  44. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatric. Infect. Dis. J. 2005, 24 (5): S58-S61.
  45. Wendelboe A.M., Nlamkepo.E., Bourillon A. et al. Transmissison of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 2007, 26 (4): 293-299.
  46. World Health Organization. Pertussis vaccines: WHO position paper. Weekly Epidemiol. Rec. 2010, 85(40):385-400. URL: http://www.who.int/wer/2010/wer8540.pdf (по состоянию на 30.05.2012).
  47. Yeh S.H., Mink C.M. Schift in the epidemiology of perussis infection: an indication for pertussis vaccine boosters for adults? Drugs. 2006, 66 (6): 731-741.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Zaytsev E.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies